Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1989 1
2001 1
2004 1
2008 2
2009 1
2012 2
2013 4
2014 1
2015 2
2017 2
2018 3
2019 5
2020 3
2021 3
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
van Kempen ZLE, Hogenboom L, Toorop AA, Steenhuis M, Stalman EW, Kummer LYL, van Dam KPJ, Bloem K, Ten Brinke A, van Ham SM, Kuijpers TW, Wolbink GJ, Loeff FC, Wieske L, Eftimov F, Rispens T, Strijbis EMM, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. Among authors: bloem k. Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2. Ann Neurol. 2023. PMID: 36250739 Free PMC article.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
Toorop AA, Hogenboom L, Bloem K, Kocyigit M, Commandeur NWM, Wijnants A, Lissenberg-Witte BI, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: bloem k. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):487-493. doi: 10.1136/jnnp-2022-330793. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693720
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH; BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. Pan S, et al. Among authors: bloem k. Clin Transl Sci. 2020 Mar;13(2):400-409. doi: 10.1111/cts.12725. Epub 2020 Jan 29. Clin Transl Sci. 2020. PMID: 31995663 Free PMC article.
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.
Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. Tsakok T, et al. Among authors: bloem k. JAMA Dermatol. 2019 Nov 1;155(11):1235-1243. doi: 10.1001/jamadermatol.2019.1783. JAMA Dermatol. 2019. PMID: 31532460 Free PMC article.
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.
Berkhout LC, l'Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, Nurmohamed MT, van Vollenhoven RF, Boers M, Alvarez DF, Smith CH, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: bloem k. Sci Transl Med. 2019 Jan 30;11(477):eaat3356. doi: 10.1126/scitranslmed.aat3356. Sci Transl Med. 2019. PMID: 30700574 Clinical Trial.
37 results